NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New attack treatment tested for rare autoimmune nerve disease
Disease control Recruiting nowThis study is testing if the drug eculizumab can help people with neuromyelitis optica spectrum disorder (NMOSD) during a sudden, severe attack. The drug is already approved to prevent these attacks, but researchers want to see if it can also stop damage and improve symptoms quic…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for halting devastating neurological attacks
Disease control Recruiting nowThis study aims to see if adding the drug eculizumab to standard steroid treatment is better at controlling severe attacks of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the nerves. It will involve 200 Chinese adults who are having a new…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Phase: PHASE4 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC